Palomino Laboratories (PALX) EBT (2023 - 2025)

Palomino Laboratories has disclosed EBT across 3 years of filings, most recently posting -$1.6 million for Q3 2025.

• EBT for Q3 2025 came in at -$1.6 million, down 1383621.55% year-over-year; the trailing twelve-month figure through Sep 2025 was -$1.8 million (down 1467.92% YoY), and the FY2024 annual result was -$145866.0, down 73.78% from the prior year.
• EBT came in at -$1.6 million for Q3 2025 at Palomino Laboratories, down from -$43775.0 in the prior quarter.
• In the past five years, EBT ranged from a high of $116.0 in Q3 2024 to a low of -$1.6 million in Q3 2025.
• The 3-year median for EBT is -$42863.0 (2023), against an average of -$218910.4.
• Across the five-year window, EBT jumped 100.27% in 2024 and tumbled 1383621.55% in 2025, its largest moves.
• Palomino Laboratories' EBT stood at -$32574.0 in 2023, then sank by 323.53% to -$137962.0 in 2024, then slumped by 1063.28% to -$1.6 million in 2025.
• The last three EBT figures came in at -$1.6 million (Q3 2025), -$43775.0 (Q2 2025), and -$25156.0 (Q1 2025), per Business Quant data.